GSK beat Q3 2026 earnings estimates as specialty medicine sales grew
Published . Updated .
Vaccine sales fell 2% and restructuring charges cut total operating profit 16%, while GSK held its 2026 guidance
Directly affected
- GSK Gsk-6.3% 10d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “medicine” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “medicine” (pharma and health) in this story.
- LLY Eli Lilly and+12.6% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “medicine” (pharma and health) in this story.
- JNJ Johnson & Johnson+0.5% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “medicine” (pharma and health) in this story.
- PFE Pfizer+8.4% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “medicine” (pharma and health) in this story.
- MRK Merck-2.1% 15d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “medicine” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| GSK | -1.79% | -0.43% | base | after close | after close | after close | after close |
| XLV | -0.15% | +0.03% | base | after close | after close | after close | after close |
| XBI | -1.35% | -3.43% | base | after close | after close | after close | after close |
| LLY | -0.83% | -0.57% | base | after close | after close | after close | after close |
| JNJ | -4.13% | -1.82% | base | after close | after close | after close | after close |
| PFE | +0.23% | +0.74% | base | after close | after close | after close | after close |
| MRK | +5.67% | +2.42% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
GSK beat Q3 2026 earnings estimates as specialty medicine sales grew Quartz
Source: Quartz
The price since 28 Oct 2026: Select Sector Spdr Tr (XLV) versus the S&P 500
| Company | When | Move | Status |
|---|---|---|---|
| GSK | three days earlier | -0.43% | final price |
| GSK | five days earlier | -1.79% | final price |
| Johnson & Johnson (JNJ) | three days earlier | -1.82% | final price |
| Johnson & Johnson (JNJ) | five days earlier | -4.13% | final price |
| Eli Lilly (LLY) | three days earlier | -0.57% | final price |
| Eli Lilly (LLY) | five days earlier | -0.83% | final price |
| Merck (MRK) | three days earlier | +2.42% | final price |
| Merck (MRK) | five days earlier | +5.67% | final price |
| Pfizer (PFE) | three days earlier | +0.74% | final price |
| Pfizer (PFE) | five days earlier | +0.23% | final price |
| Spdr Series Trust (XBI) | three days earlier | -3.43% | final price |
| Spdr Series Trust (XBI) | five days earlier | -1.35% | final price |
| Select Sector Spdr Tr (XLV) | three days earlier | +0.03% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | -0.15% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 54 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 33 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 50 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 54 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 54 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 68 days before publication. Filed 8 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 31 Jul 2026. That is 89 days before publication. Filed 22 Sep 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 34 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 70 days before publication. Filed 9 Sep 2026. View the filing.
- Donald J Trump, an executive branch official, sold Merck (MRK), worth $250,001 - $500,000 on 31 Jul 2026. That is 89 days before publication. Filed 22 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Select Sector Spdr Tr (XLV)
Companies mentioned with this story
- XLV Select Sector Spdr Tr
Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence in the 28 Oct 2026 story “GSK beat Q3 2026 earnings estimates as specialty medicine sales grew.” Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “medicine” (pharma and health) in this story
- XBI Spdr Series Trust
For “GSK beat Q3 2026 earnings estimates as specialty medicine sales grew,” Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence. Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “medicine” (pharma and health) in this story
- LLY Eli Lilly
For “GSK beat Q3 2026 earnings estimates as specialty medicine sales grew,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “medicine” (pharma and health) in this story
- JNJ Johnson & Johnson
For “GSK beat Q3 2026 earnings estimates as specialty medicine sales grew,” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “medicine” (pharma and health) in this story
- PFE Pfizer
Pfizer (PFE) is linked, with no stored direction, medium confidence in the 28 Oct 2026 story “GSK beat Q3 2026 earnings estimates as specialty medicine sales grew.” Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “medicine” (pharma and health) in this story
- MRK Merck
In “GSK beat Q3 2026 earnings estimates as specialty medicine sales grew,” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “medicine” (pharma and health) in this story
Select Sector Spdr Tr (XLV)
On 28 Oct 2026, “GSK beat Q3 2026 earnings estimates as specialty medicine sales grew” is the story that connects Select Sector Spdr Tr (XLV) to this story.
For Select Sector Spdr Tr (XLV), the reason on file says Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “medicine” (pharma and health) in this story
Spdr Series Trust (XBI) is here too. Its reason reads: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “medicine” (pharma and health) in this story
Price levels for Select Sector Spdr Tr (XLV)
LLY traded between 1131.55 and 1321.17 across 20 sessions. The latest close on file is 1282.03. XBI traded between 152.63 and 158.97 across 2 sessions. The latest close on file is 154.01. XLV traded between 166.19 and 168.74 across 2 sessions. The latest close on file is 167.68.
How strong the case is around Select Sector Spdr Tr (XLV)
46 out of 100
“GSK beat Q3 2026 earnings estimates as specialty medicine sales grew” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.